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Infectious bursal disease virus (IBDV) is a double-stranded RNA (dsRNA) virus of the Birnaviridae family. Its
two genome segments are encapsidated together with multiple copies of the viral RNA-dependent RNA
polymerase, VP1, in a single-shell capsid that is composed of VP2 and VP3. In this study we identified the
domains responsible for the interaction between VP3 and VP1. Using the yeast two-hybrid system we found that
VP1 binds to VP3 through an internal domain, while VP3 interacts with VP1 solely by its carboxy-terminal 10
amino acids. These results were confirmed by using a reverse-genetics system that allowed us to analyze the
interaction of carboxy-terminally truncated VP3 molecules with VP1 in infected cells. Coimmunoprecipitations
with VP1- and VP3-specific antibodies revealed that the interaction is extremely sensitive to truncation of VP3.
The mere deletion of the C-terminal residue reduced coprecipitation almost completely and also fully abolished
production of infectious virions. Surprisingly, these experiments additionally revealed that VP3 also binds to
RNA. RNase treatments and reverse transcription-PCR analyses of the immunoprecipitates demonstrated that
VP3 interacts with dsRNA of both viral genome segments. This interaction is not mediated by the carboxy-
terminal domain of VP3 since C-terminal truncations of 1, 5, or 10 residues did not prevent formation of the
VP3-dsRNA complexes. VP3 seems to be the key organizer of birnavirus structure, as it maintains critical
interactions with all components of the viral particle: itself, VP2, VP1, and the two genomic dsRNAs.
Infectious bursal disease virus (IBDV) is the causative agent
of a highly contagious disease of young chickens. IBDV mul-
tiplies rapidly in developing B lymphocytes in the bursa of
Fabricius, leading to immunosuppression and increased sus-
ceptibility to other diseases. Of the two IBDV serotypes, only
serotype 1 is pathogenic to chickens (23). IBDV belongs to the
family Birnaviridae (17). Members of this family are character-
ized by a double-stranded RNA (dsRNA) genome consisting
of two segments (A and B) that are packaged within a single-
shell icosahedral capsid of 60 nm.
The smaller genome segment, B, of IBDV (approximately
2.9 kb) encodes a single protein, viral protein 1 (VP1; 91 kDa).
This protein is the putative RNA-dependent RNA polymerase
(12). It has the intriguing feature of occurring in virions in two
forms: a form in which it is covalently bound to the 5 ends of
the genomic dsRNA segments (viral protein genome-linked
[VPg]) (16) and a free-polypeptide form. The larger dsRNA
segment, A (approximately 3.3 kb), contains two partly over-
lapping open reading frames (ORFs). The first ORF encodes
nonstructural protein VP5 (17 kDa). This protein proved to be
nonessential for viral replication and infection (33, 41). The
second ORF encodes a 110-kDa polyprotein, which is auto-
catalytically cleaved to give pVP2 (48 kDa), VP4 (28 kDa), and
VP3 (32 kDa). The viral protease VP4, through a catalytic site
belonging to the Lon protease family, is responsible for this
self-processing of the polyprotein (5, 27, 35). During virus
maturation, the precursor pVP2 is further processed into ma-
ture VP2 (40 kDa), probably as a result of a site-specific cleav-
age of pVP2 by VP4 protease activity (25, 27).
VP2 and VP3 are the major viral structural proteins. They
form the proteinaceous capsid, the structure of which was
shown by cryoelectron microscopy and image reconstruction to
exhibit a T13 lattice (10, 13). The capsid shell is composed of
homotrimeric subunits of VP2 and VP3; 260 VP2 trimers con-
stitute the outer surface, while the 200 Y-shaped VP3 trimers
line the inner surface. Consistently, VP2 carries the major
neutralizing epitopes (2, 4), while it has been suggested that
VP3, by virtue of its basic carboxy-terminal domain, interacts
with the packaged dsRNA (10, 22).
While these ultrastructural studies already provided impor-
tant insight into the general architecture of the virus, essen-
tially nothing is yet known about the specific interactions be-
tween the different viral components and how these give rise to
the formation of viral particles. We and others recently re-
ported that VP3 is able to associate with VP1 (30, 36). We
showed that VP1-VP3 complexes are formed in the cytoplasm
of IBDV-infected cells and eventually released into the cell
culture medium, suggesting that the viral polymerase is incor-
porated into virions through interactions with the inner capsid
protein (36). Likewise, Lombardo et al. (30) showed that VP1
is efficiently incorporated into IBDV virus-like particles pro-
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duced in mammalian cells coexpressing the IBDV polyprotein
and VP1.
In the present study we have followed up on these suppos-
edly essential interactions. By using the yeast two-hybrid sys-
tem as well as by mutagenesis of an infectious cDNA clone of
the virus we mapped the domain in VP3 interacting with VP1
to the extreme carboxy-terminal tail of the polypeptide. This
interaction appeared not to be required for negative-strand
RNA synthesis but appeared to be crucial for the production of
infectious progeny virus as deletion of just the carboxy-termi-
nal residue was sufficient to abolish virus replication. These
investigations also revealed that VP3 additionally binds to viral
dsRNA, both of the A segment and of the B segment, and that
it does so through a domain distinct from that binding to VP1.
MATERIALS AND METHODS
Cells, viruses, plasmids, and antisera. QM5 cells (1) were cultured in QT35
medium (Gibco-BRL) supplemented with 5% fetal calf serum and 2% antibiotic
solution ABII (1,000 U of penicillin [Yamanouchi], 1 mg of streptomycin [Ra-
diumfarma], 20 g of amphotericin B [Fungizone], 500 g of polymixin B, and
10 mg of kanamycin/ml) in a CO2 (5%) incubator at 37°C. The classical IBDV
isolate CEF94 is a derivate of PV1 which has been adapted for growth in cell
cultures (8, 34). Recombinant fowlpox virus expressing the T7 polymerase gene
(FPV-T7) (11) was received from the laboratory of M. Skinner (Compton Lab-
oratory, Berks, United Kingdom). The preparation of the plasmids pHB36W (A
segment) and pHB34Z (B segment), which contain full-length genomic cDNA of
IBDV strain CEF94, has been described (8). Polyclonal rabbit antisera against
VP1 and VP3 were produced by injecting rabbits with purified recombinant VP1
or VP3 (7, 36). A monoclonal antibody (MAb) directed against VP3 (MAb C3)
was kindly provided by H. Mu¨ller (University of Leipzig, Leipzig, Germany).
Construction of two-hybrid expression plasmids. Copy DNA encoding the
full-length sequences of VP1 and VP3 of IBDV strain CEF94 or defined parts
thereof (see Fig. 1) were amplified by PCR by using the Expand high-fidelity
PCR system (Boehringer Mannheim). Plasmid pHB36W was used as the DNA
template for preparing the VP3 constructs, and plasmid pHB34Z was used for
the VP1 constructs. The sets of primers used were designed to introduce an
EcoRI site at the upstream (5) end and a stop codon plus either a SalI site (VP3
constructs) or an XhoI site (VP1 constructs) at the downstream (3) end of each
coding sequence (Table 1). PCR products were precipitated, digested with
EcoRI and SalI (VP3 PCR fragments) or with EcoRI and XhoI (VP1 PCR
fragments), gel purified by the QIAEX-II method (Qiagen), and ligated with T4
DNA ligase (New England BioLabs) into the yeast expression vectors pLexABD
and pB42AD (Clontech). These vectors had previously been digested with EcoRI
and XhoI. The ligation mixture was transformed into Escherichia coli DH5- cells
(Life Technologies), which were subsequently grown under ampicillin selection.
Plasmid DNA prepared from several independent transformants was screened
for the presence of the insert, and plasmids from positive clones were sequenced
at the fusion junction by cycle sequencing with an ABI 310 sequencer (Perkin-
Elmer) to ensure correct reading frames.
Two-hybrid analysis. All two-hybrid media, buffers, and protocols were pre-
pared and used as described by Clontech (manual for the Matchmaker LexA
two-hybrid system and Yeast Protocols Handbook). The yeast strain Saccharomy-
ces cerevisiae EGY48 (Clontech) was transformed by using the lithium acetate
method with the URA3 plasmid p8op-lacZ (Clontech), which has a lacZ re-
porter gene preceded by an upstream LexA binding domain. Transformed cells
were amplified and subsequently cotransformed with pLexABD (HIS3) and
pB42AD (TRP1) constructs carrying the VP1 cDNA (or fragments thereof) and
the VP3 cDNA (or segments thereof). Control plasmids were pLexABD-bicoid
(pRHFM1; OriGene) and pB42AD-empty. Transformants were plated onto glu-
cose-supplemented synthetic dropout medium (SD) lacking His, Ura, and Trp
(SD/Glu/His/Ura/Trp medium). His Ura Trp colonies from each
transformation were subsequently plated onto SD/Gal/raffinose (Raf)/His/
Ura/Trp/Leu medium to assess the transcriptional activation of the LEU2
reporter gene and onto SD/Gal/Raf/5-bromo-4-chloro-3-indolyl--D-galactopyr-
anoside (X-Gal)/His/Ura/Trp medium to assess the transcriptional activa-
tion of the lacZ reporter gene. Transformants containing plasmids pLexABD-53
(Clontech) and pB42AD-SV40 T (Clontech), in which 53 codes for the murine
p53 protein, known to physically associate strongly with simian virus 40 large T
antigen (14, 28), served as a positive control to assess assay conditions.
Modification of the full-length cDNA clone of IBDV segment A. Plasmid
pHB36W was used for oligonucleotide-directed mutagenesis to introduce stop
codons in the 3-terminal region of the coding strand of VP3 by PCR. Primers
p139, p140, p141, and p142 (Table 1), each containing one or more nucleotide
substitutions to create these stop codons, were used in combination with primer
p138 (Table 1).
The resulting PCR fragments were digested with BglII and KpnI, purified with
an agarose gel (Qiaex gel extraction kit), and ligated (Rapid ligation kit; Boehr-
inger Mannheim) into the full-length segment A clone (pHB36W), which had
been digested with the same restriction enzymes. The ligation mixture was
subsequently used to transform E. coli DH5- cells (Life Technologies). To
confirm the correct nucleotide sequences of the pHB36W derivates, desig-
nated pHB36W-VP31(tag), pHB36W-VP31(tga), pHB36W-VP35(tga), and
pHB36W-VP310(tga), we determined the nucleotide sequence of the ex-
changed part (BglII/KpnI fragment). Two independently obtained plasmids of
each pHB36W derivate were used for in vitro transcription and translation and
for transfection of QM5 cells.
In vitro transcription and translation. In vitro T7 polymerase-driven expres-
sion was carried out by using the TNT Quick coupled transcription-translation
system (Promega) as described by the manufacturer, except that reactions were
performed in a final volume of 2.5 l. Plasmid pHB36W or its derivatives (0.4
g) were used as the template. The resulting viral proteins were resolved in 12%
separating gels by sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) and visualized by autoradiography.
Transfection of QM5 cells. QM5 cells were grown to 80% confluence in
60-mm-diameter dishes and infected with FPV-T7 (multiplicity of infection 3).
After 1 h, the cells were washed once with 5 ml of QT35 medium and covered
with 5 ml of Optimem 1 (Gibco-BRL). In the meantime, 2.0 g of DNA was
mixed with 25 l of Lipofectamine (Gibco-BRL) in 0.5 ml of Optimem 1 and
kept at room temperature for at least 30 min. The QM5 cells were subsequently
covered with 4 ml of fresh Optimem 1, and the DNA-Lipofectamine mixture was
added. The transfection was performed overnight (18 h) in a 37°C incubator
(5.0% CO2). The transfected monolayer was rinsed once with QT35 medium,
and fresh QT35 medium supplemented with 5% fetal calf serum and 2% ABII
was added. The plates were further incubated for another 24 h.
Radiolabeling of transfected cells, immunoprecipitation, and gel electro-
phoresis. At 48 h posttransfection, cells were starved for 1 h in methionine-free
Eagle’s minimal essential medium (EMEM) (Gibco-BRL). Cells were then la-
beled for 3 h with 20 Ci of [35S]methionine (Amersham)/ml in methionine-free
EMEM. At the end of the labeling, the cell cultures were lysed on ice in 1	
phosphate-buffered saline (PBS)-TDS lysis buffer by using a 5	 PBS-Triton-
sodium deoxycholate-SDS (TDS) lysis buffer stock solution (5% Triton X-100,
2.5% sodium deoxycholate, 0.5% SDS, 0.7 M NaCl, 14 mM KCl, 50 mM
Na2HPO4, 7.5 mM KH2PO4). Cell debris was removed by centrifugation at 4°C
for 20 min at 13,000 	 g. All lysates were pretreated with protein A-Sepharose
(Amersham) prior to being immunoprecipitated with polyclonal anti-VP1 serum
or monoclonal anti-VP3 (MAb C3) serum. Protein A-Sepharose-bound immune
complexes were washed three times in 1	 PBS-TDS lysis buffer and eluted in 30
l of SDS sample buffer (60 mM Tris-HCl [pH 6.8], 2.5% SDS, 5% -mercap-
toethanol, 10% glycerol, 0.1% bromophenol blue). Proteins were resolved in
12% separating gels by SDS-PAGE and visualized by autoradiography.
RNase treatment of immunoprecipitates. Before SDS-PAGE the protein A-
Sepharose-bound immune complexes were resuspended in 10 l of 10 mM
Tris-HCl (pH 7.5) and treated as follows. For RNaseONE treatment, the im-
munoprecipitates were incubated for 45 min at 37°C with 1,000 U of RNaseONE
(Promega)/ml in 10 mM Tris-HCl (pH 7.5)–5 mM EDTA–200 mM sodium
acetate. RNaseONE, an RNase able to cleave a phosphodiester bond between
any two ribonucleotides, catalyzes the degradation of single-stranded RNA (ss-
RNA) to cyclic nucleotide monophosphate intermediates (Promega). For RNase
A treatment, the immunoprecipitates were incubated for 45 min at 37°C with
RNase A at a concentration of 100 g/ml in 10 mM MgCl2. RNase A is often
considered an ssRNA-specific enzyme, though at a low salt concentration (i.e., 10
mM MgCl2) it degrades both ssRNA and dsRNA (29). At the end of the RNase
treatments the Sepharose beads were collected and washed three times with 1	
PBS-TDS lysis buffer, after which the immune complexes were eluted in 30 l of
SDS-sample buffer and subjected to SDS-PAGE.
RT-PCR analysis of immunoprecipitates. For the negative- and positive-
strand-specific reverse transcription-PCR (RT-PCR) of segments A and B, 1 l
of the respective immunoprecipitates was used. To prime cDNA synthesis on the
genomic positive and negative strands of segment A, we used oligonucleotides
pA() and pA(), which hybridized to nucleotides (nt) 271 to 295 and 2852 to
2877 of the plus and minus strands, respectively (Table 1). To prime cDNA
synthesis on the genomic positive and negative strands of segment B, we used
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TABLE 1. Nucleotide sequences and positions of the primers used for VP1 and VP3 deletion mutagenesis, for the generation of mutant
segment A cDNA constructs, and for RT-PCR analysis
Primer Nucleotide sequencea Positionb Purposec
p009 ccgGAATTCATGAGTGACATTTTCAACAGTCCAC B (nt 112) VP1 and VP1C derivates
p110 cgtCTCGAGTCATGGCTGTTGGCGGCTCTCC B (nt 2754) VP1 and VP1N derivates
p075 ccgGAATTCCTCTTGATCCCTAAAGTTTGGGTG B (nt 202) VP1N30
p076 ccgGAATTCGTTTTGCAGCCACGGTCTCTGC B (nt 292) VP1N60
p078 ccgGAATTCCCCAATGCGTACCCGCCAGAC B (nt 472) VP1N120
p080 ccgGAATTCGAGGTCGCCACTGGAAGAAACC B (nt 652) VP1N180
p082 ccgGAATTCGGCGACTTTGAGGTTGAAGATTAC B (nt 832) VP1N240
p084 ccgGAATTCAAGAAGCTACTCAGCATGTTAAGTG B (nt 1012) VP1N300
p086 ccgGAATTCAATAACGTGTTGAACATTGAAGGGTG B (nt 1192) VP1N360
p088 ccgGAATTCGAGGCAAACTGCACTCGCCAAC B (nt 1372) VP1N420
p089 ccgGAATTCCAAACATGGGCCACCTTTGCCATG B (nt 1462) VP1N450
p104 cgtCTCGAGTCATCTGCTCGTTCCTGCTCCGAG B (nt 2664) VP1C30
p103 cgtCTCGAGTCACTGTGGGTTCTTGACTTCTGGG B (nt 2574) VP1C60
p101 cgtCTCGAGTCACTTGGACTTGTGGAGTTTCTCGG B (nt 2394) VP1C120
p099 cgtCTCGAGTCAGGGCTTGGGGGGTACTGGCTTG B (nt 2214) VP1C180
p097 cgtCTCGAGTCAGCAGGCTTTGTTCAGGAGTGGG B (nt 2034) VP1C240
p095 cgtCTCGAGTCAGAGATCTTTGCTGTATGTAGCTGAC B (nt 1854) VP1C300
p093 cgtCTCGAGTCACTCAATTGATTTGAACTCCTCGCTG B (nt 1674) VP1C360
p091 cgtCTCGAGTCAGGCAATGTTCATGGCAAAGGTGG B (nt 1494) VP1C420
p090 cgtCTCGAGTCAGGCTTGCATGTGTTGGCGAGTG B (nt 1404) VP1C450
p057 tcGAATTCGCTTCAGAGTTCAAAGAGACCCCC A (nt 2396) VP3 and VP3C derivates
p006 gatcGTCGACTCACTCAAGGTCCTCATCAGAGAC A (nt 3166) VP3 and VP3N derivates
p061 aagtGTCGACTCAGTCGACTCAGCTTGGCCCTCGGTGCCCATTG A (nt 2782) VP3C129
p060 ccgGAATTCGGCCAGCTAAAGTACTGGCAGAAC A (nt 2786) VP3N129
p063 aagtGTCGACTCAATAGACTTTGGCAACTTCGTCTATG A (nt 2977) VP3C64 and VP3N64,C64
p062 ccgGAATTCAACGCACCACAAGCAGGCAGCAAG A (nt 2588) VP3N64
p064 gatcGTCGACTCACCAGCGGCCCAGCCGACCAG A (nt 3136) VP3C10
p065 gatcGTCGACTCATGTTGGAGCATTGGGTTTTGGCTTG A (nt 3106) VP3C20
p066 gatcGTCGACTCATGGTAGAGCCCGCCTGGGATTGCG A (nt 3076) VP3C30
p067 gatcGTCGACTCACAGCTCCATCGCAGTCAAGAGCAGATC A (nt 3046) VP3C40
p068 gatcGTCGACTCACATCTGTTCTTGGTTTGGGCCACGTC A (nt 3016) VP3C50
p069 gatcGTCGACTCAGTTGATTTCATAGACTTTGGCAACTTCG A (nt 2986) VP3C60
p106 gatcGTCGACTCAAAGGTCCTCATCAGAGACGGTCC A (nt 3163) VP3C1
p107 gatcGTCGACTCAGTCCTCATCAGAGACGGTCCTG A (nt 3160) VP3C2
p108 gatcGTCGACTCAATCAGAGACGGTCCTGATCCAGC A (nt 3154) VP3C4
p109 gatcGTCGACTCAGACGGTCCTGATCCAGCGGCC A (nt 3148) VP3C6
p110 gatcGTCGACTCACCTGATCCAGCGGCCCAGCC A (nt 3142) VP3C8
p111 tcGAATTCGAAGAACAAATCCTAAGGGCAGCTAC A (nt 2882) VP3N162
p112 tcGAATTCGAAATCAACCATGGACGTGGCCC A (nt 2978) VP3N194
p113 tcGAATTCCCAAAGCCCAAGCCAAAACCCAATG A (nt 3074) VP3N226
p114 tcGAATTCATCAGGACCGTCTCTGATGAGGAC A (nt 3137) VP3N248
p138 CTCAAAGAAGATGGAGACC A (nt 2704) pHB36W derivates
p139 CAGGTACCTCACTAAAGGTC A (nt 3177) pHB36W-VP31(tag)
p140 CAGGTACCTCATCAAAGGTCC A (nt 3177) pHB36W-VP31(tga)
p141 CAGGTACCTCACTCAAGGTCCTCTCAAGAGAC A (nt 3177) pHB36W-VP35(tga)
p142 CAGGTACCTCACTCAAGGTCCTCATCAGAGACGGTCCTTCACCAGC A (nt 3177) pHB36W-VP310(tga)
pA() CCCTGACCCTGTGTCCCCCACAGTC A (nt 295) RT, ()RNA segment A
pAC1 GATCGGTCTGACCCCGGGGGAG A (nt 3) PCR, segment A specific
pANC1 TAGGTCGAGGTCTCTGACCTGAGAG A (nt 264) PCR, segment A specific
pA() GTGCATGCAGAGAAGAGCCGGTTGGC A (nt 2852) RT, ()RNA segment A
pANC2 ACCCGCGAACGGATCCAATTTGGG A (nt 3256) PCR, segment A specific
pAC2 ATCTACGGGGCTCCAGGACAGGC A (nt 2912) PCR, segment A specific
pB() GGGCGATGTGTTGGGTAGTACTTTGGG B (nt 458) RT, ()RNA segment B
pBC1 ATACGATGGGTCTGACCCTCTGGG B (nt 3) PCR, segment B specific
pBNC1 GGAAGTACTCCTGATCTCCAATAGGG B (nt 433) PCR, segment B specific
pB() GGGTTCCCACTCGACGAGTTCCTAGC B (nt 2077) RT, ()RNA segment B
pBNC2 CCCCCGCAGGCGAAGGCCGGG B (nt 2822) PCR, segment B specific
pBC2 TGAGCTGTCAGAGTTCGGTGAGGC B (nt 2112) PCR, segment B specific
a The primer sequences are listed 5 to 3. Restriction sites are in italics. Additional nucleotides 5 of a restriction site are in lowercase. Boldface letters indicate an
in-frame stop codon. Mutated nucleotides are underlined.
b A and B, A and B segment plus strands, respectively; A and B, A and B segment minus strands, respectively.
c ()RNA, plus strand RNA; ()RNA, minus strand RNA.
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oligonucleotides pB() and pB(), which hybridized to nt 432 to 458 and 2077
to 2102 of the plus and minus strands, respectively (Table 1). For RT, samples
containing 1 l of the immunoprecipitate and 2 pmol of the primer in a total
volume of 10 l were incubated at 98°C for 2 min and immediately chilled on ice.
Subsequently, 10 l of an RT mixture containing 2	 Superscript II first-strand-
synthesis buffer (Gibco-BRL), 20 mM dithiothreitol, 1 mM (each) deoxynucleo-
side triphosphate, and 200 U of Superscript II (Gibco-BRL) was added. For the
negative-control reaction, the addition of Superscript II enzyme was omitted.
The RT reaction was carried out at 50°C for 60 min, after which the incubation
was continued at 70°C for 15 min to inactivate the RT. The reaction products
were amplified by PCR using primer pairs pAC1-pANC1 for the plus strand of
segment A (yielding a PCR product of 262 bp corresponding to nt 3 to 264),
pAC2-pANC2 for the minus strand of segment A (yielding a 345-bp PCR prod-
uct corresponding to nt 2912 to 3256), pBC1-pBNC1 (yielding a 431-bp PCR
product corresponding to nt 3 to 433) for the plus strand of segment B, and
pBC2-pBNC2 for the minus strand of segment B (yielding a 711-bp product
corresponding to nt 2112 to 2822) (Table 1). The PCR consisted of 25 cycles,
each comprising 15 s of denaturation at 94°C, 30 s of annealing at 68°C, and 45 s
of elongation at 72°C. The 25 cycles were followed by a 90-s incubation at 72°C.
Detection of infectious rescued IBDV. To rescue infectious virus, transfected
cells and culture fluid were freeze-thawed three times and the supernatant was
filtered through a 200-nm-pore-size filter (Acrodisc; Gelman Sciences) to re-
move the FPV-T7 and cellular debris. The cleared supernatant was either stored
at 20°C or used directly for further analysis. Infectious rescued IBDV was
detected by inoculating a subconfluent monolayer of QM5 cells with part of the
cleared supernatant. After incubation for 48 h at 37°C the cells were washed with
PBS, dried, and stored at 20°C until an immunoperoxidase monolayer assay
was performed by using a polyclonal antiserum against VP3 (39).
RESULTS
A carboxy-terminal binding site in VP3 is responsible for
VP1-VP3 interaction. The yeast two-hybrid system (20, 21, 38)
is an increasingly popular tool for the detection of protein-
protein interactions. Here we used the system to map the
domains responsible for the VP1-VP3 interaction. Various
truncated versions of VP1 and VP3 were inserted into the
plexABD (“bait”) and pB42AD (“prey”) yeast expression plas-
mids. An interaction between the bait and prey fusion proteins
allows yeast cells containing both plasmids to grow on medium
lacking leucine and to produce -galactosidase (-Gal), giving
rise to blue colonies on X-Gal-containing medium. The
strength of the protein-protein interaction can be judged by the
intensity of the blue phenotype, allowing a semiquantitative
evaluation of the interaction between the candidate proteins
(18, 28, 40). As positive controls, a combination of plasmids
pLexABD-VP1 and pB42AD-VP3 and the reciprocal combina-
tion pLexABD-VP3 and pB42AD-VP1, each one containing a
complete gene, were tested, and these produced the expected
phenotypes. Individually, or in combination with the respective
control plasmids pLexABD-bicoid and pB42AD-empty, these
constructs were negative in both assays, confirming the speci-
ficity of the test system.
To map the interacting domain of VP3, five different dele-
tion mutants were initially generated: VP3C129 and
VP3N129, in which the carboxy-terminal and amino-terminal
halves of VP3 were deleted, VP3C64 and VP3N64, lacking
64 amino acids at either end, and VP3N64,C64, missing 64
amino acids from both termini of the protein (Fig. 1B, I).
Similarly, a large series of amino- and carboxy-terminal-dele-
tion mutants were generated for VP1 (Fig. 1A). The coding
region of each of the deletion mutants was expressed by both
pLexABD and pB42AD expression vectors, and the products
were tested for their capability to interact with wild-type VP1
or VP3. To rule out the possibility of nonspecific transactiva-
tion of the reporter genes, all constructs were additionally as-
sayed for reporter gene activation when expressed either alone
or together with the respective control plasmids pLexABD-
bicoid and pB42AD-empty. Since all constructs proved to be
negative in these tests (data not shown), all interactions be-
tween the LexABD and B42AD fusion proteins were regarded
as specific. The results of the assays for the VP1-VP3 interac-
tion are presented in Fig. 1. Of the VP1 deletion mutants, both
carboxy- and amino-terminally truncated fusion proteins
scored positive in the test assessing production of -Gal and
growth on medium lacking Leu, except for the mutants with an
amino- or carboxy-terminal truncation of 240 amino acids or
larger (Fig. 1A). These results suggest that the internal core
domain of VP1 is essential for the VP3 interaction. For the
domain mapping of VP3 the results showed that a deletion of
64 amino acids or more at the carboxy terminus completely
abolished binding to VP1, whereas the deletions at the amino
terminus had no effect on this interaction (Fig. 1B, I). This
indicated that the carboxyl terminus of VP3 is critical for the
VP1-VP3 interaction.
To determine the interacting domain in VP3 more precisely,
we constructed and tested six progressive-carboxy-terminal-
deletion mutants, lacking 10, 20, 30, 40, 50, and 60 amino acids.
None of these mutants showed reporter gene activation, sug-
gesting that the binding domain of VP3 is located within the
last 10 amino acids of the carboxyl terminus (Fig. 1B, II). We
therefore constructed and tested five additional carboxy-termi-
nal-deletion mutants lacking 1, 2, 4, 6, and 8 amino acids. Each
of these deletion mutants had VP1 binding activity, albeit ac-
tivity weaker than that of wild-type VP3 (Fig. 1B, III). To
confirm these findings, we also tested a series of VP3 proteins
with amino-terminal deletions by removing up to 248 of the
258 amino acids of the protein. All these truncated proteins,
even the mutant VP3N248, consisting of just the 10-residue
carboxy-terminal domain of VP3, conferred growth on Leu
medium and gave blue colonies on X-Gal-containing medium
(Fig. 1B, IV).
Collectively, these yeast two-hybrid experiments consistently
identified the 10-amino-acid carboxy-terminal peptide of VP3
as the VP1 interaction domain. To independently confirm this
conclusion and to study the function of the VP1-VP3 interac-
tion, we made use of our reverse-genetics system (9) to gen-
erate viral VP3 carboxy-terminal-deletion mutants.
In vivo interaction between VP1 and carboxy-terminally
truncated VP3. To test for a functional role for the VP1-VP3
interaction during IBDV replication, mutant IBDV cDNA
clones of the full-length segment A were constructed by intro-
ducing stop codons in the 3 terminus of the coding strand
to generate carboxy-terminally truncated VP3 mutants.
cDNA clones pHB36W-VP310(tga), pHB36W-VP35(tga),
pHB36W-VP31(tga), and pHB36W-VP31(tag), containing
a stop at codon positions 10, 5, or 1 preceding the natural stop
codon of the VP3 gene, were prepared (Fig. 2). In all mutants
the original codon was replaced by a TGA stop codon except
in clone pHB36W-VP31(tag), where a TAG stop codon,
which required only a single point mutation (GAG to TAG),
was used.
To analyze the expression and processing of the viral pro-
teins of the mutated A segments, in vitro transcriptions and
translations were performed by using a rabbit reticulocyte sys-
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tem. The radiolabeled translation products were subsequently
analyzed by SDS-PAGE and autoradiography (Fig. 3). In all
cases the viral polyprotein was processed normally into pVP2,
VP3, and VP4. As predicted, the apparent molecular mass of
VP3 decreased with increasing deletions: the removal of 5 or
10 carboxy-terminal amino acids gave rise to an apparent re-
duction in molecular mass of some 1 to 2 kDa.
To study more directly the role of the VP3 carboxy-terminal
FIG. 1. Mapping of the VP1-VP3 binding domain(s) by using deletion mutagenesis and the yeast two-hybrid system. Schematic representations
of the deletion mutations in VP1 and VP3 are presented. VP1 and VP3 deletion mutants were cloned into pLexABD and pB42AD yeast expression
vectors and tested for their ability to interact with full-length VP3 and full-length VP1, respectively. Interactions were assayed for leucine
autotrophy (Leu) and for -Gal activity (LacZ). For Leu, symbols are as follows: , clear growth (strong interaction); , growth (interaction);
, no growth (no interaction); for LacZ, symbols are as follows: , deep blue colonies (very strong interaction); , blue colonies (strong
interaction); , light blue colonies (interaction); , white colonies (no interaction). All results shown are representative of those for at least seven
independent transformants. AA, amino acids.
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domain in the interaction with VP1, we coexpressed the pro-
teins in cells using the cotransfection system described previ-
ously (9). The wild-type and mutated full-length segment A
cDNA clones, pHB36W, pHB36W-VP31(tag), pHB36W-
VP31(tga), pHB36W-VP35(tga), and pHB36W-VP310
(tga), were each transfected into QM5 cells together with ei-
ther the wild-type full-length segment B cDNA clone
(pHB34Z) or a mutant full-length segment B cDNA clone
named pMB13 (Fig. 4A). The last clone was used as a negative
control for virus replication. In this clone, the stem-loop struc-
ture in the 3 terminus of the coding strand predicted by Boot
et al. (8) was changed into a more stable stem-loop structure by
the replacement of three adjacent cytosine residues (nt 2802 to
2804) by three guanines, which resulted in a construct that
failed to yield virus in combination with wild-type segment A
cDNA (6). Forty-eight hours posttransfection, cells were met-
abolically labeled for 3 h with [35S]methionine and subse-
quently subjected to immunoprecipitation with either anti-VP1
or anti-VP3 serum. The immunoprecipitates obtained were
analyzed by SDS-PAGE, and the labeled proteins were visu-
alized by autoradiography. As shown in Fig. 4B, top, when the
anti-VP3 serum was used, comparable amounts of the full-
length and the truncated VP3 proteins were detected in the
transfected QM5 cells. VP1 was clearly coprecipitated with
full-length VP3 but only in minor amounts with the carboxy-
terminally truncated VP31 (lanes 1 to 3). The immunopre-
cipitations of VP35 and VP310 (lanes 4 to 5) completely
failed to coprecipitate detectable amounts of VP1. This is in
contrast with the anti-VP1 immunoprecipitations, where VP1
and VP3 were both present in all immunoprecipitates (lanes 1
to 5). The same results were found with the pMB13-cotrans-
fected QM5 cells (lanes 6 to 10), indicating that productive
viral replication is not required for VP1-VP3 binding. For
IBDV strain CEF94 we recently showed that the free VP1
protein occurs in two forms with molecular masses of 90 and 95
kDa (36). In IBDV-infected cells both these forms appeared to
interact with VP3 initially after their translation, though the
interaction with the 90-kDa form gradually became undetect-
able thereafter (36). These observations explain the presence
of the two discrete bands of free VP1 in the 90- to 95-kDa size
range seen in the anti-VP1 immunoprecipitates (Fig. 4B to D),
while only the 95-kDa band appears in the anti-VP3 immuno-
precipitates; apparently only the 95-kDa form of VP1 inter-
acted with VP3 and therefore was coprecipitated when the
anti-VP3 serum was used.
FIG. 2. Schematic representation of mutagenesis of the segment A cDNA clone. Plasmid pHB36W, containing the full-length cDNA sequence
of segment A preceded by a T7 promoter sequence and followed by the autocatalytic hepatitis delta virus ribozyme (HDR) and a T7 terminator,
is shown at the top. The nucleotide sequence of the 3 terminus of the ORF for the polyprotein is depicted below. The TGA stop codon of VP3
is underlined. Mutated nucleotides are boxed, and introduced stop codons are indicated below in boldface. The generated plasmids are
pHB36W-VP310(tga), pHB36W-VP35(tga), pHB36W-VP31(tga), and pHB36W-VP310(tag), according to the position and kind of stop
codon in the 3 terminus of the coding sequence of VP3. UTR, untranslated region.
FIG. 3. Autoradiogram of an SDS-PAGE analysis of a coupled in
vitro transcription-translation reaction. Plasmids containing the full-
length A segment, pHB36W (lane 1), pHB36W-VP31(tag) (lane 2),
pHB36W-VP31(tga) (lane 3), pHB36W-VP35(tga) (lane 4), and
pHB36W-VP310(tga) (lane 5), were used as the DNA template to
produce the viral proteins. The positions of the viral proteins and the
sizes of the marker proteins (lane M) are indicated.
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FIG. 4. Radioimmunoprecipitation analysis of VP1-VP3 interaction in transfected QM5 cells. (A) QM5 cells were (co)transfected with the
indicated plasmids containing either the wild-type or a mutated cDNA of the A segment and/or B segment. At 48 h posttransfection cells were
metabolically labeled for 3 h with [35S]methionine. Subsequently, cells were lysed and immunoprecipitated with anti-VP3 serum (VP3) or with
anti-VP1 serum (VP1) followed by SDS-PAGE, either directly (B) or after an RNaseONE (C) or RNase A treatment (D). Positions of the viral
proteins and sizes of marker proteins (in kilodaltons) are indicated.
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Furthermore, with the exception of the controls of the trans-
fected A segment or B segment alone (Fig. 4B to D, lanes 11
to 13), all immunoprecipitations revealed the presence of sev-
eral bands in the high-molecular-mass region of 
97 kDa
(lanes 1 to 10). Our previous studies have shown that these
bands are VP1 specific and represent VP1-RNA complexes, as
ascertained by Western blot analysis using VP1-specific sera
and RNase treatment (36). It was obvious that these VP1-
RNA complexes were present in both the VP1-specific and the
VP3-specific immunoprecipitates. Since, in the latter case, nei-
ther VP35 nor VP310 was able to coprecipitate VP1, we
speculated that the presence of these VP1-RNA complexes in
the VP3-specific immunoprecipitates might be a consequence
of a direct VP3-RNA interaction rather than of a VP1-VP3
interaction. This assumption would also explain the unex-
pected coprecipitation of VP35 and VP310 proteins when
the VP1 antibodies were used. The observation that the
amount of coprecipitated VP3 correlated with the amount of
precipitated VP1-RNA complex rather than with the amount
of precipitated VP1 (lanes 1 to 5 and 6 to 10) also supports this
interpretation. We therefore analyzed the sensitivity of the
immune complexes to RNase.
VP3 interacts both with VP1 and with IBDV-specific dsRNA.
To study the VP1-VP3 interaction per se, i.e., without the
interference of RNA-mediated coimmunoprecipitation, we
performed an RNase treatment on all the VP1-specific and
VP3-specific immunoprecipitates. To distinguish between
ssRNA and dsRNA, we performed RNaseONE and RNase A
treatment, thereby degrading specifically ssRNA or both
ssRNA and dsRNA, respectively. The RNaseONE treatment
failed to degrade the VP1-RNA complexes (Fig. 4C). The
electrophoretic patterns of both the VP1- and VP3-specific
coimmunoprecipitates were indistinguishable from those pre-
sented in Fig. 4B, indicating that the integrity of the VP1-RNA
complexes is not dependent on ssRNA. In contrast, in the
RNase A-treated samples, no high-molecular-mass (
97-kDa)
complexes were present (Fig. 4D; lanes 1 to 13). Hence, the
VP1-RNA complexes were maintained by dsRNA. Further-
more, in the VP3-specific immunoprecipitations, VP1 was co-
precipitated with full-length VP3 and, to a lesser extent, with
VP31 but not with VP35 and VP310. The reciprocal im-
munoprecipitations fully confirmed these results. The VP1 an-
tiserum coprecipitated full-length VP3 and, again in much
smaller amounts, VP31 (clearly seen after a prolonged expo-
sure of the autoradiograph; data not shown). Obviously,
VP35 and VP310 were no longer coprecipitated in the ab-
sence of dsRNA. Apparently, VP3 is able to associate with the
VP1-dsRNA complexes through direct VP3-dsRNA interac-
tion.
It was therefore of interest to determine whether the dsRNA
in these complexes represented IBDV genome segment A-
and/or B-specific sequences. To this end, we performed an
RT-PCR analysis. The untreated and RNaseONE- and RNase
A-treated VP3-specific immunoprecipitates were analyzed for
the presence of positive- and negative-strand genomic RNA.
As expected, RT-PCR products specific for the 5 ends of both
strands of both segments were obtained from the untreated
and RNaseONE-treated samples but not from the RNase A-
treated samples (Table 2; data for the RNaseONE-treated
samples are not shown). The finding that no product was ob-
tained when reverse transcriptase was omitted from the reac-
tion mixture before PCR indicates that the PCR products were
derived from RNA, not from contaminating DNA. In cells
transfected with either pHB36W or pHB34Z alone, no RT-
PCR products were obtained, confirming the absence of
IBDV-specific VP1-dsRNA complexes in these immunopre-
cipitates. Plasmids pHB36W and pMB13, which are known to
be incapable of generating infectious progeny virus when co-
transfected into cells, appeared to be RNA replication com-
petent as shown by the RT-PCR products obtained (Table 2).
Hence, the RNaseONE-resistant but RNase A-sensitive high-
molecular-mass material in the radioimmunoprecipitation
analysis of this combination (Fig. 4B to D, lanes 6 to 10) was of
IBDV-specific dsRNA origin. Infection induced in cells by
using pMB13 and pHB36W is probably affected at the level of
particle assembly or the particles produced are somehow not
infectious.
As the RT-PCR analysis was performed with primers de-
signed to amplify 5-end sequences from plus as well as minus
strand RNA, the results indicate that full-length dsRNA was
present in the immunoprecipitates. Consequently, the higher-
molecular-mass material of 220 kDa, which had barely en-
tered the gel in the immunoprecipitation assays, most likely
represents the full-length dsRNA-VPg complexes. The smear
below it suggests the presence of incomplete dsRNA molecules
such as VPg linked to partial dsRNA molecules, consisting of
one full-length strand and one partial, complementary strand;
this material runs faster than the full-length dsRNA-VPg com-
plexes and appears as a smear due to its heterogeneity (15, 26).
When full-length dsRNA-VPg complexes from another birna-
virus, infectious pancreatic necrosis virus, were treated with
RNase by Magyar et al. (31), VPg molecules carrying oligonu-
cleotides that had survived the enzymatic treatment, suppos-
edly due to steric hindrance by the unusually large VPg, were
obtained. The two discrete bands seen migrating at 110 to
150 kDa might therefore represent two forms of VPg linked to
short oligonucleotides that were inaccessible to RNase. Inter-
TABLE 2. RT-PCR analysis of the anti-VP3 immunoprecipitation
reactions of Fig. 4B and D
Transfected plasmid for segment:
Result of strand-specific RT-PCR with
indicated primers for samplesa:
Untreated RNase A treated
A B A A B B A A B B
pHB36W pHB34Z        
pHB36W-VP31(tag) pHB34Z        
pHB36W-VP31(tga) pHB34Z        
pHB36W-VP35(tga) pHB34Z        
pHB36W-VP310(tga) pHB34Z        
pHB36W        
pHB34Z        
pHB36W pMB13        
a Specific positive-sense and negative-sense primers of segments A and B (A,
A, B, and B, respectively) were used for RT. Following RT, the reaction
products were amplified by PCR using specific primer pairs based on 5 terminal
sequences of both the positive and negative strands of segments A and B (for
details, see Materials and Methods). The plus and minus signs indicate the
presence or absence of a specific PCR product. Controls, in which reverse
transcriptase was omitted from the reaction, were negative.
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estingly, these short VPg-linked oligonucleotides were not re-
sistant to RNase A treatment.
Altogether, these observations supported the results of the
yeast two-hybrid screen with the truncated VP3 deletion mu-
tants. In addition, they revealed that the (co)precipitated VP1-
RNA complexes contained genomic dsRNA and that VP3 is
able to associate with these complexes by interacting directly
with the dsRNA.
VP1-VP3 interaction is essential for the generation of infec-
tious progeny. To analyze the truncated-VP3 viral mutants,
VP31(tag), VP31(tga), VP35(tga), and VP310(tga), for
their ability to produce infectious virus, we examined the trans-
fection supernatants of these mutants for the presence of re-
combinant IBDV. Aliquots of the supernatants were inocu-
lated onto fresh monolayers of QM5 cells, which were
subsequently incubated for 48 h and fixed. An IBDV-specific
antibody assay was used to analyze whether infection had oc-
curred. In none of the assays could IBDV proteins be detected
in the QM5 monolayer except for the wild-type situation,
where unmodified segments A and B had originally been trans-
fected (data not shown). These results indicate that all mutant
viruses were unable to generate infectious progeny.
DISCUSSION
Little is yet known about the nature and significance of the
interactions between the viral components during the IBDV
life cycle. Here we focused on the viral capsid protein VP3. We
demonstrated that its interaction with VP1 is critically medi-
ated by its carboxy-terminal domain. The removal of just the
terminal residue was sufficient to affect its association with VP1
and inhibited the production of infectious progeny completely.
The VP3 protein also appeared to interact with both segments
of the viral dsRNA. Our results thus point to an essential role
in virus morphogenesis for VP3, which is involved not only in
the formation of the capsid shell but also in the incorporation
of the genome and the viral RNA polymerase.
The VP3 domain interacting with VP1 was unambiguously
mapped to the carboxy-terminal tail by two independent ap-
proaches. In yeast two-hybrid analyses the ability to associate
with VP1 was lost when 10 or more terminal residues of VP3
were removed while, conversely, the corresponding decapep-
tide by itself was able to establish an interaction. These assays
additionally demonstrated that the VP1 protein interacts with
VP3 through its more internal domain, but further mapping
thereof was not pursued. Site-directed mutagenesis of our in-
fectious cDNA clone revealed that in IBDV infection the in-
teraction between the two proteins is even more sensitive to
changes in the VP3 carboxy-terminal tail. The mere deletion of
the ultimate residue dramatically affected the strength of their
association, as judged by the almost complete loss of their
interaction in the coimmunoprecipitation assay and the com-
plete loss of infectious-virus production.
These studies unexpectedly led us to the detection of the
VP3-dsRNA interactions. The key observation here was that
higher-molecular-mass material, which, as we observed earlier,
contains VPg-linked RNA (36), was immunoprecipitated with
anti-VP3 serum from lysates of cells undergoing infection with
VP35 and VP310 mutant virus (Fig. 4B). Because this ma-
terial was unlikely to have been precipitated through interac-
tion of the mutant VP3 molecules with VPg (free VP1 was
clearly not coprecipitated from these lysates), a direct VP3-
RNA interaction seemed most plausible. RNase treatments
subsequently confirmed this interpretation, demonstrating in
addition that the interaction was double strand specific: RNase
A but not the single-strand-specific RNaseONE degraded the
immune complexes. Furthermore, RT-PCR analysis substanti-
ated that the RNA was indeed of IBDV origin and that it
contained both positive and negative strands of each of the two
genome segments. As the RT primers were designed to amplify
the 5 end sequence from the plus or minus RNA strand, the
results indicated that full-length dsRNA was produced. Less
dsRNA-linked VP1 was detected in cells expressing the C-
terminally truncated proteins VP35 and VP310 than in cells
expressing wild-type VP3 or VP31, suggesting that the VP3
truncations either affect the capacity of VP3 to associate with
dsRNA or impair dsRNA synthesis by affecting the capacity of
VP1 to function as a replicase, transcriptase, or primase. Wild-
type VP3 was found predominantly in association with the
dsRNA-linked form of VP1, relatively little being associated
with free VP1. This may indicate that not all free VP1 is bound
to VP3 during infection. Alternatively, the observation might
have been brought about by the experimental conditions used:
there may have been differences in the efficiencies with which
the different complexes (VP3-VP1 versus VP3-VPg-dsRNA)
were immunoprecipitated, or the amount of anti-VP3 antibod-
ies may have been limiting. VP3 is probably synthesized in
excess of VP1 (VP3 constitutes 40% of the virion protein, and
VP1 constitutes only 3% [17). Limiting VP3 antibodies would
be expected to favor the precipitation of dsRNA-VP1-VP3
complexes over free VP1-VP3 complexes as the former prob-
ably carry relatively more VP3. Finally it is of note that the
same autoradiographic patterns were obtained in different ra-
dioimmunoprecipitation assays, both with transfected and with
infected cells, by using different labeling periods and different
labeling times (data not shown), indicating that the results
obtained in the present coimmunoprecipitation analysis were
not skewed by unlabeled VP1 and VP3 formed prior to met-
abolic labeling.
Our results finally provide experimental evidence for the
long-anticipated role of VP3 in binding to viral nucleic acids.
In 1986 Hudson et al. (22) proposed such a role on the basis of
the polypeptide’s primary sequence. These investigators no-
ticed that the predicted carboxy-terminal domain, with 12 pos-
itively charged residues (and 8 prolines) among its last 40
residues, is highly basic in nature. Interestingly, the terminal
stretch of this domain is, in contrast, very acidic, with four
negatively charged amino acids being present within the last
five residues. This suggests that VP3 might possess two func-
tional domains within its carboxy terminus: the extreme termi-
nal part, which binds to VP1, and the positively charged do-
main immediately upstream thereof, which binds the viral
dsRNA. Future mutation analyses will be required to experi-
mentally confirm the role of the latter domain.
Knowledge about the morphogenesis of birnaviruses is still
very limited. Most of what we know came from studies in which
IBDV cDNAs were expressed in cells using vaccinia virus or
baculovirus systems (13, 19, 30, 32, 37). These studies revealed
that virus-like particles indistinguishable from authentic viri-
ons can be assembled just from the segment A-derived
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polyprotein precursor (19, 30). It appears that correct particle
assembly is not dependent on the presence of viral RNA or
VP1 or of the small protein VP5, also specified by segment A,
but rather that it merely requires the proteins pVP2 and VP3,
the latter acting as an internal scaffold (32). VP1 was coincor-
porated into such particles to an extent similar to that to which
it was coincorporated into virions when its cDNA was coex-
pressed with segment A cDNA (30). These investigations in
addition pointed to an important role of the carboxy-terminal
tail of pVP2 in the assembly of the T13 capsid, this terminal
region being crucially involved in the control of the interac-
tions among VP2 trimers and between VP2 trimers and VP3
trimers (13).
The results demonstrate that the VP3 protein is a key orga-
nizer in birnavirus morphogenesis. By its interactions with all
the structural components in the virion it appears to create the
interior architecture that is required for the proper execution
of the replication and transcription activities that are the hall-
mark of dsRNA viruses. It is now clear that VP3 entertains
interactions with itself, with VP2, with free VP1 molecules,
most likely also with genome-bound VP1, and with dsRNA
segments A and B. Different domains in the protein are re-
sponsible for these different interactions. The carboxy-terminal
domains binding to the dsRNAs and to VP1 are, for instance,
distinct from the region involved in the homotypic interactions
giving rise to the VP3 trimers that have been observed in viral
particles by ultrastructural analyses (10, 13; M. G. J. Tacken et
al., unpublished data). We have not yet explored the domain(s)
in the homotrimeric VP3 complex interacting with the ho-
motrimeric VP2 complexes that constitute the outer surface of
the viral capsid.
Of particular interest are the interactions of VP3 with VP1
and VPg. These interactions are obviously of critical impor-
tance, as the various activities embodied in the polymerase
protein are essential for the virus life cycle. Though we did not
provide direct evidence for it, we assume that VP3 interacts
with VPg and that the interacting domains in VP1 and VPg are
the same. Free VP1 molecules present in virions have been
shown to carry covalently bound, short stretches of viral RNA,
presumably 5-terminal sequences (24). Their association with
VP3 suggests that VP1 does not bind through the domain that
contains the serine residue by which these oligonucleotides are
attached and also by which VPg is linked to genomic RNA. It
is therefore more likely that VP1 and VPg both bind through
another, but identical, domain. It will be interesting to find out
if and how the virus regulates the numbers of free and genome-
bound VP1 molecules assembled in each viral particle. Higher-
resolution structural analyses may shed light on this question
and establish whether free VP1 and VPg assume distinct and
specific positions within the internal virion cavity. Precise spa-
tial arrangements are likely to be required within the virion for
the expeditious functioning of this replication and transcrip-
tion machine.
dsRNA viruses of higher eukaryotes invariably contain mul-
tiple genome segments. It is still an unresolved issue how these
segments are correctly assorted during particle assembly.
Among these viruses the birnaviruses are exceptional because
of their genome-linked polymerase protein VPg, the other
viruses all having a cap structure associated with the 5end of
the positive RNA strand of each segment. A role for the VPg
moiety in the selection of the genome segments is therefore
conceivable. Alternatively, this selection might be achieved by
VP3 through its capacity to bind dsRNA. This capacity might
of course also assist in the proper positioning of the two
dsRNA segments within the virion. We have not investigated
whether the dsRNA binding activity of VP3 is sequence spe-
cific and, if so, whether the sequences recognized are segment
specific or occur in the common terminal genomic regions. If
this dsRNA binding activity indeed operates at the level of
segment selection during particle assembly, we assume that
VP3 binds to specific double-stranded regions within the viral
mRNAs, as all dsRNA viruses are assumed to synthesize their
negative RNA strand only after the packaging of their mR-
NAs. The specific encapsidation of IBDV mRNAs might thus
resemble the mechanism by which the hepatitis B virus assem-
bles its pregenomic RNA. Here the viral polymerase binds to
a specific stem-loop structure present in viral mRNAs, which
subsequently leads to the polymerase-dependent encapsida-
tion of the viral nucleic acid (3, 42). Much work will be re-
quired to resolve these issues, not only for IBDV but also for
the other dsRNA viruses. It is expected that continued molec-
ular-virology studies in combination with the ultrastructural
analyses in progress will allow us to answer the many outstand-
ing questions concerning the biology of these viruses.
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